{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:57:48Z","timestamp":1790467068200,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["No.17K08732"],"award-info":[{"award-number":["No.17K08732"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The clinicopathological characteristics and prognostic factors in nodal peripheral T-cell lymphomas (PTCLs) with two or more T follicular helper markers (TFH+) are not adequately investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Immunohistologically, we selected 22 patients with TFH+ lymphoma (PTCL-TFH) in 47 of PTCL-not otherwise specified (NOS), and subclassified into large and small cell groups. We compared the two groups with 39 angioimmunoblastic T-cell lymphoma (AITL) and seven follicular T-cell lymphoma (F-TCL) patients. Prognostic factors were analysed by overall survival in patients with three types of TFH+ PTCLs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirteen large cell and nine small cell PTCL-TFH patients had more than two TFH markers including programmed cell death-1 (PD-1). Large cell PTCL-TFH showed frequent CMYC expression in 10 patients (77%), and four of 11 large cell group (36%) had somatic <jats:italic>RHOA<\/jats:italic> G17V gene mutation by Sanger sequencing. Large cell PTCL-TFH patients showed significantly worse prognosis than those of the small cell group, AITL, and F-TCL (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In TFH+ PTCLs, CMYC+ tumour cells, and combined PD-1 ligand 1 (PD-L1)\u2009+\u2009tumour cells and intense reaction of PD-L1+ non-neoplastic cells (high PD-L1+ cell group) were significantly poor prognostic factors (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Combinations of CMYC+ or PD-1+ tumour cells and high PD-L1+ cell group indicated significantly poor prognosis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Large cell PTCL-TFH indicated poor prognosis in TFH+ PTCLs. These data suggested that CMYC+ tumour cells and intense PD-L1+ cell reaction influenced tumour cell progression in TFH+ PTCLs, and PD-1+ tumour cell\/intense PD-L1+ cell reactions may play a role in immune evasion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-021-01163-7","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T08:02:44Z","timestamp":1636185764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell\/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers"],"prefix":"10.1186","volume":"16","author":[{"given":"Yasuhito","family":"Mihashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kawauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Shimajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morishige","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2016.08.003","volume":"43","author":"H Ueno","year":"2016","unstructured":"Ueno H. T follicular helper cells in human autoimmunity. Curr Opin Immunol. 2016;43:24\u201331. https:\/\/doi.org\/10.1016\/j.coi.2016.08.003.","journal-title":"Curr Opin Immunol"},{"key":"1163_CR2","first-page":"407","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"A Dogan","year":"2017","unstructured":"Dogan A, Gaulard P, Jaffe ES, M\u00fcller-Hermelink HK, de Leval L. Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2017. p. 407\u201312."},{"issue":"12","key":"1163_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1097\/PAS.0b013e31817f123e","volume":"32","author":"SM Rodr\u0131guez-Pinilla","year":"2008","unstructured":"Rodr\u0131guez-Pinilla SM, Atienza L, Murillo C, P\u00e9rez-Rodr\u00edguez A, Montes-Moreno S, et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol. 2008;32(12):1787\u201399. https:\/\/doi.org\/10.1097\/PAS.0b013e31817f123e.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"1163_CR4","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1097\/PAS.0000000000001315","volume":"43","author":"BM Basha","year":"2019","unstructured":"Basha BM, Bryant SC, Rech KL, Feldman AL, Vrana JA, Shi M, et al. Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype. Am J Surg Pathol. 2019;43(9):1282\u201390. https:\/\/doi.org\/10.1097\/PAS.0000000000001315.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1163_CR5","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","volume":"102","author":"MP Dobay","year":"2017","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148\u201351. https:\/\/doi.org\/10.3324\/haematol.2016.158428.","journal-title":"Haematologica"},{"issue":"12","key":"1163_CR6","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: are port of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402\u20138. https:\/\/doi.org\/10.1182\/blood-2010-09-310342.","journal-title":"Blood"},{"issue":"15","key":"1163_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376. https:\/\/doi.org\/10.1182\/blood-2018-09-872549.","journal-title":"Blood"},{"issue":"3","key":"1163_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/PAS.0000000000000365","volume":"39","author":"KM Chisholm","year":"2015","unstructured":"Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39(3):294\u2013303. https:\/\/doi.org\/10.1097\/PAS.0000000000000365.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1163_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","volume":"36","author":"TM Green","year":"2012","unstructured":"Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, M\u00f8ller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36(4):612\u20139. https:\/\/doi.org\/10.1097\/PAS.0b013e318244e2ba.","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"1163_CR10","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1182\/blood-2014-06-578856","volume":"124","author":"RL Starza","year":"2014","unstructured":"Starza RL, Borga C, Barba G, Pierini V, Schwab C, et al. Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood. 2014;124(24):3577\u201382. https:\/\/doi.org\/10.1182\/blood-2014-06-578856.","journal-title":"Blood"},{"issue":"8","key":"1163_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/PAS.0000000000000871","volume":"41","author":"Y Mihashi","year":"2017","unstructured":"Mihashi Y, Mizoguchi M, Takamatsu Y, Ishitsuka K, Iwasaki H, Koga M, et al. C-MYC and its main ubiquitin ligase, FBXW7, influence cell proliferation and prognosis in adult T-cell leukaemia\/lymphoma. Am J Surg Pathol. 2017;41(8):1139\u201349. https:\/\/doi.org\/10.1097\/PAS.0000000000000871.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"1163_CR12","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.3324\/haematol.2016.143768","volume":"101","author":"R Manso","year":"2016","unstructured":"Manso R, Bellas C, Martin-Acosta P, Mollejo M, Menarguez J, Rojo F, et al. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica. 2016;101(8):e336\u20138. https:\/\/doi.org\/10.3324\/haematol.2016.143768.","journal-title":"Haematologica"},{"issue":"6282","key":"1163_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumour immune response through CD47 and PD-L1. Science. 2016;352(6282):227\u201331. https:\/\/doi.org\/10.1126\/science.aac9935.","journal-title":"Science"},{"issue":"11","key":"1163_CR14","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s00432-019-03025-8","volume":"145","author":"C Zhou","year":"2019","unstructured":"Zhou C, Che G, Zheng X, Qiu J, Xie Z, Cong Y, et al. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145(11):2663\u201374. https:\/\/doi.org\/10.1007\/s00432-019-03025-8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1163_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","volume":"71","author":"A Kythreotou","year":"2018","unstructured":"Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018;71(3):189\u201394. https:\/\/doi.org\/10.1136\/jclinpath-2017-204853.","journal-title":"J Clin Pathol"},{"issue":"7","key":"1163_CR16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/his.13475","volume":"72","author":"A Sakakibara","year":"2018","unstructured":"Sakakibara A, Kohno K, Eladl AE, Klaisuwan T, Ishikawa E, Suzuki Y, et al. Immunohistological assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-reed Sternberg (HRS)-like cells. Histopathol. 2018;72(7):1156\u201363. https:\/\/doi.org\/10.1111\/his.13475.","journal-title":"Histopathol"},{"key":"1163_CR17","doi-asserted-by":"publisher","unstructured":"Tiemann M, Samoilova V, Atiakshin D, Buchwalow I. Immunophenotyping of the PD-L1-positiv cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Res Notes. 2020;13:139. https:\/\/doi.org\/10.1186\/s13104-020-04975-w.","DOI":"10.1186\/s13104-020-04975-w"},{"issue":"11","key":"1163_CR18","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1080\/10428194.2019.1602266","volume":"60","author":"M Sun","year":"2019","unstructured":"Sun M, Su W, Qian J, Meng H, Ji H, Liu Y, et al. The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2019;60(11):2646\u201357. https:\/\/doi.org\/10.1080\/10428194.2019.1602266.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1163_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41379-019-0336-3","volume":"33","author":"J Shen","year":"2020","unstructured":"Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, et al. PD-L1 expression is associated with ALK positivity and STAT3 activity, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2020;33(3):324\u201333. https:\/\/doi.org\/10.1038\/s41379-019-0336-3.","journal-title":"Mod Pathol"},{"issue":"1","key":"1163_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00428-020-02790-z","volume":"447","author":"S Kim","year":"2020","unstructured":"Kim S, Kwon D, Koh J, Nam SJ, Kim YA, Kim TM, et al. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. Virch Arch. 2020;447(1):131\u201342. https:\/\/doi.org\/10.1007\/s00428-020-02790-z.","journal-title":"Virch Arch"},{"issue":"8","key":"1163_CR21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/PAS.0000000000000651","volume":"40","author":"R Nagao","year":"2016","unstructured":"Nagao R, Kikuchi YY, Carreras J, Kikuchi T, Miyaoka M, et al. Clinicopathologic analysis of angioimmunoblastic T-cell lymphoma with or without RHOA G17V mutation using formalin-fixed paraffin-embedded sections. Am J Surg Pathol. 2016;40(8):1041\u201350. https:\/\/doi.org\/10.1097\/PAS.0000000000000651.","journal-title":"Am J Surg Pathol"},{"key":"1163_CR22","first-page":"403","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SA Pileri","year":"2017","unstructured":"Pileri SA, Weisenburger DD, Sng I, Nakamura S, M\u00fcller-Hermelink HK, Chan WC, et al. Peripheral T-cell lymphoma, NOS. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2017. p. 403\u20136."},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"16124","DOI":"10.18632\/oncotarget.24592","volume":"9","author":"R Manso","year":"2018","unstructured":"Manso R, Gonzalez-Rincon J, Rodriguez-Justo M, Roncador G, G\u00f3mez S, et al. Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. Oncotarget. 2018;9:16124\u201333. https:\/\/doi.org\/10.18632\/oncotarget.24592.","journal-title":"Oncotarget"},{"issue":"5","key":"1163_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","volume":"33","author":"Y Huang","year":"2009","unstructured":"Huang Y, Moreau A, Dupuis J, Petit B, Le Gouill S, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2009;33(5):682\u201390. https:\/\/doi.org\/10.1097\/PAS.0b013e3181971591.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1163_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41379-018-0108-5","volume":"32","author":"S Hartmann","year":"2019","unstructured":"Hartmann S, Goncharova O, Portyanko A, Sabattini E, Meinel J, K\u00fcppers R, et al. CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. Mod Pathol. 2019;32(1):37\u201347. https:\/\/doi.org\/10.1038\/s41379-018-0108-5.","journal-title":"Mod Pathol"},{"issue":"2","key":"1163_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/PAS.0b013e3181cc7e79","volume":"34","author":"C Krishnan","year":"2010","unstructured":"Krishnan C, Warnke RA, Arber DA, Natkunam Y. PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol. 2010;34(2):178\u201389. https:\/\/doi.org\/10.1097\/PAS.0b013e3181cc7e79.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"1163_CR27","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1080\/10428194.2021.1881511","volume":"62","author":"R Manso","year":"2021","unstructured":"Manso R, Rodr\u00edguez-Perales S, Torres-Ruiz R, Santonja C, Rodr\u00edguez-Pinilla SM. PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements. Leuk Lymph. 2021;62(7):1648\u201356. https:\/\/doi.org\/10.1080\/10428194.2021.1881511.","journal-title":"Leuk Lymph"},{"issue":"23","key":"1163_CR28","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.1158\/0008-5472","volume":"74","author":"S Schubbert","year":"2014","unstructured":"Schubbert S, Cardenas A, Chen H, Garcia C, Guo W, Bradner J, et al. Targeting the MYC and PI3K pathways eliminates leukaemia-initiating cells in T-cell acute lymphoblastic leukaemia. Cancer Res. 2014;74(23):7048\u201359. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"issue":"18","key":"1163_CR29","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","volume":"131","author":"S Casey","year":"2018","unstructured":"Casey S, Baylot V, Felsher DW. The MYC oncogene is a global regulator of immune response. Blood. 2018;131(18):2007\u201315. https:\/\/doi.org\/10.1182\/blood-2017-11-742577.","journal-title":"Blood"},{"issue":"5","key":"1163_CR30","doi-asserted-by":"publisher","first-page":"e1581529","DOI":"10.1080\/2162402X.2019.1581529","volume":"8","author":"Y Pan","year":"2019","unstructured":"Pan Y, Feia Q, Xiong P, Yang J, Zhang Z, et al. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Oncoimmunology. 2019;8(5):e1581529. https:\/\/doi.org\/10.1080\/2162402X.2019.1581529.","journal-title":"Oncoimmunology"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-021-01163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-021-01163-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-021-01163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T20:04:56Z","timestamp":1636229096000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-021-01163-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1186\/s13000-021-01163-7","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Ethics Committee of Fukuoka University and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board of Fukuoka University, Faculty of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}